To evaluate the possible role of TNF-α/NF-κB1 pathway in anti-angiogenic therapy-induced CD47 upregulation, the tumor-bearing mice were simultaneously treated with VEGF inhibitor and BAY 11–7082 (TNF-α/NF-κB1 inhibitor). The gene discussed is CD47; the disease is neoplasm.